

## Drug and Therapeutics Committee – Minutes –unapproved

<b>Date / Time</b>	Thursday 8 <sup>th</sup> December 2016
<b>Venue</b>	The Board Room, Alderson House, HRI
<b>Chair</b>	Dr O Ogunbambi, Consultant Rheumatologist
<b>Notes / Action Points</b>	Mrs Susan Greene, Senior Pharmacy Technician (SG)
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Mr P O'Brien, Deputy Chief Pharmacist Mr R Kapur, Vascular Surgeon Dr F Umerah, Consultant Anaesthetist Dr H Klonin, Consultant Paediatrician Mr K McCorry, Medicines Management, East Riding
-------------------	---

<b>Apologies</b>	Prof A Morice, Chair, Professor of Respiratory Medicine Prof M Lind, Vice Chair, Professor of Oncology Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Dr Roper, Chair, Hull CCG
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2016.12.01	<b>Apologies</b>	As above.					
2016.12.02	<b>Declarations of Interest</b>	None					
2016.12.03	<b>Minutes of the previous meeting</b>	The minutes were accepted as a true record.					12/16
2016.12.04	<b>Action Tracker</b>	<b>New Product Requests - Tedizolid</b> It had previously been agreed that this can be used as a 2 <sup>nd</sup> line agent for a short course (e.g. 6 days) orally and this is covered within the PbR tariff. Long term use is not within tariff, so has not been approved. This had been discussed further, but the position remains unchanged.	Tedizolid approved for short course use, as an ALERT antibiotic/Red drug	Action Complete			12/16
2016.12.04	<b>Action Tracker</b>	<b>NICE Guidance – July 16</b>  TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa POB has confirmed that NHSE have now identified HEY as a centre for this condition and we will be commissioned to use Adalimumab in HS. A D&T new product request would be sought from the service. POB had contacted Greg Haire and was awaiting a response.  TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer	Ongoing  ML had requested an application	POB awaiting response from Greg Haire  Action Complete	POB	8/16	12/16

2016.12.04	Action Tracker	<p><b>New product requests</b></p> <p><b>Dexmedetomidine (Dexdor) – Dr I Smith</b> OO had written to the applicant. SG had updated the formulary.</p> <p><b>Diamorphine Nasal Spray (Ayendi) – Dr E Herrieven</b> DC had added to SMPC agenda for further discussion regarding handling &amp; storage as a controlled drug</p> <p><b>Recombinant Factor IX &amp; VII Blood Clotting Factors agents – Dr D Allsup</b></p> <ul style="list-style-type: none"> <li>• Elocta® (efmoroctocog alfa, Swedish Orphan Biovitrum)</li> <li>• Nuwiq® (simoctocog alfa, Octapharma)</li> <li>• Rixubis® (nonacog gamma, Baxalta/Shire)</li> <li>• Alprolix® (eftrenonacog alfa, Swedish Orphan Biovitrum)</li> <li>• Idelvion® (albutrepenonacog alfa, CSL Behring)</li> </ul> <p><b>NICE Guidance – August 2016</b> TA 401- Bosutinib for previously treated chronic myeloid leukaemia TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer TA391 - Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel</p> <p><b>NICE Guidance – September 2016</b> TA406- Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer</p> <p>TA407 - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors</p> <p>TA408 - Pegaspargase for treating acute lymphoblastic leukaemia</p>		<p>Actions completed</p> <p>Action completed</p> <p>SG had updated the formulary</p> <p>ML had requested these applications</p> <p>ML had requested an application</p> <p>SG had updated formulary &amp; added to MMIG agenda</p> <p>ML had requested an application</p>			<p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p>
------------	----------------	--	--	--	--	--	--

2016.12.04	<b>Action Tracker</b>	<p><b>Correspondence Received - Ivermectin cream/Rosacea pathway – Dr R Zaman</b> SPG had requested a revised document from Dr Zaman, but had not received a reply yet.</p> <p><b>Anticoagulation for children, shared care with Leeds – tinzaparin &amp; heparin IV infusion chart – Ann Kristensen</b></p> <p><b>Stalevo &amp; generic switching -</b> SPG had asked Jane Morgan to get feedback from Dr Ming, Consultant Neurologist, HEY. Dr Ming had reported multiple patients with loss of symptom control. Some were severe, with 1 patient being admitted to hospital for re-titration of dose. This was with both Stanek and Sastravi products.</p> <p>Also, a yellow card ADR form had been sent to Dr Ming, as the company has had no reports of any incidents when switching patients.</p> <p><b>Diclofenac Review</b> POB had asked the F&amp;W HG Pharmacist to raise at their HG governance meeting.</p>		Action completed			12/16
2016.12.05	<b>New Product Requests</b>	<p><b>Cantharone and Cantharone Plus- Dr Gowda</b> Approved as RED drug, as unlicensed in UK, for professional application by Dermatology. It was queried how young a child would be treated. Confirmation of lower age limit needed.</p> <p><b>Enstilar (calcipotriol &amp; betamethasone dipropionate) Topical Cutaneous Foam Spray – Dr R. Zaman</b></p> <p><b>Obinutuzumab (Gazyva) – Dr D Allsup</b></p> <p><b>Descovy® (Emtricitabine/ Tenofovir Alafenamide Or F/TAF –</b></p>	Approved	SG to add to formulary	SG	01/17	12/16
				OO to write to applicant, and request information on child age limit	OO	01/17	
			Approved	SG to add to formulary	SG	01/17	
			Approved	SG to add to formulary	SG	01/17	
			Approved	SG to add to	SG	01/17	

		<b>L. Cullen</b>		formulary			
		<b>Odefsey® (Rilpivirine/ Emtricitabine/ Tenofovir Alafenamide/ Or RPV/F/TAF) – L. Cullen-</b>	Approved	SG to add to formulary	SG	01/17	
		<b>Zepatier® (Elbasvir / Grazoprevir ) – L. Cullen</b>	Approved	SG to add to formulary	SG	01/17	
2016.12.06	<b>NICE Guidance</b>	<p><b>October 2016</b></p> <ul style="list-style-type: none"> <li>• TA413 - Elbasvir–grazoprevir for treating chronic hepatitis C</li> <li>• TA 414 - Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma – Not recommended by NICE</li> <li>• TA 415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor</li> <li>• TA 416 - Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer</li> <li>• CG 155 - Psychosis-and-schizophrenia in children and young people : recognition and management</li> <li>• CG 98 - Jaundice in newborn babies under 28 days</li> </ul> <p><b>November 2016</b></p> <ul style="list-style-type: none"> <li>• NG 57 - Physical health of people in prison</li> <li>• NG58 - Coexisting severe mental illness and substance misuse: community health and social care services</li> <li>• NG 59 - Low back pain and sciatica in over 16s: assessment and management</li> <li>• TA 417- Nivolumab for previously treated advanced renal cell carcinoma</li> </ul>	<p>Approved, as above</p> <p>Not on formulary</p> <p>Already On Formulary</p> <p>Not on formulary</p> <p>Not for HEY</p> <p>Formulary not affected</p> <p>Not for HEY</p> <p>Not for HEY</p> <p>All already on formulary</p> <p>Not on formulary</p>	<p>No further Action</p> <p>No further Action</p> <p>No Further Action</p> <p>ML to seek application</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>ML to request an application</p>			<p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>12/16</p> <p>ML</p> <p>12/16</p>

		<ul style="list-style-type: none"> <li>TA 418 - Dapagliflozin in triple therapy for treating type 2 diabetes</li> <li>TA 419 - Apremilast for treating moderate to severe plaque psoriasis</li> <li>NG 18 - Diabetes (type 1 and type 2) in children and young people: diagnosis and management</li> <li>CG 190 - Intrapartum care for healthy women and babies care</li> <li>TA 288 - Dapagliflozin in combination therapy for treating type 2 diabetes – Includes dapagliflozin for triple therapy</li> <li>CG145 - Spasticity in under 19s: management</li> <li>CG127 - Hypertension in adults: diagnosis and management</li> <li>CG95 - Chest pain of recent onset: assessment and diagnosis</li> </ul>	On formulary & guidelines	No further action			12/16
			On formulary for existing patients only	SG to change formulary to “in line with TA419”			12/16
			Update does not affect formulary	No further action			12/16
			Update does not affect formulary	No further action			12/16
			On formulary & guidelines	No further action			12/16
			Update does not affect formulary	No further action			12/16
			Update does not affect formulary	No further action			12/16
			Update does not affect formulary	No further action			12/16
2016.12.07	<b>MHRA Drug Safety Update</b>	<p><b>October 2016</b> Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis It was suggested that KMcC should obtain local prescribing data, to be discussed at MMIG. OO to discuss with Rheumatology colleagues</p> <p><b>November 2016</b> Brimonidine gel (Mirvaso ▼): risk of exacerbation of rosacea Currently non-formulary, as application deferred pending production of treatment pathway</p>	Review local prescribing data	KMcC to obtain for MMIG	KMcC	01/17	
			OO to discuss with colleagues	OO to brief colleagues	OO	01/17	
			No further action				12/16
2016.12.08	<b>Minutes from SMPC July 2016</b>	DC was not present - deferred to next month. HK Raised concerns over a prescribing safe haven on wards.	Noted, but not an issue for D&T	POB to feed back to DC	POB	01/17	

2016.12.09	<b>Minutes from the HERPC July 2016</b>	Contents noted	No Further Action				12/16
2016.12.10	<b>Correspondence Received</b>	<p>Pemetrexed Generic. – Lilly (Manufacturer) are seeking patent protection for the use of co-prescribed folic Acid and vitamin B<sub>12</sub> whilst patient is taking the generic version of this drug. This co-prescription is standard practice and should continue, in the patients' best interest.</p> <p>Heparin IV Prescription (Paediatrics) This had been developed by Leeds and would facilitate shared care for children having care in Leeds and Hull. As this use was common there would be less risk of errors by using the same drug, doses and chart. It was suggested that a box was added for prescriber GMC number, in line with other HEY prescription charts</p> <p>Dronedarone poster &amp; NICE TA 197 checklist (both updated)</p>	<p>Noted, but to continue current practice and await further national guidance</p> <p>Approved</p> <p>Approved</p>	<p>No Further Action</p> <p>SG to feed back to Paediatric Pharmacist</p>	<p>SG</p>	<p>01/17</p>	<p>12/16</p> <p>12/16</p>
2016.12.11	<b>Chairs approvals</b>	<ul style="list-style-type: none"> <li>• Belatacept (Nulojx)- Kidney transplant- Dr M Eady Discussions are still ongoing, as NHSE IFR was initially rejected.</li> <li>• Xultophy- Type 2 diabetes-Dr B Allan</li> <li>• Avastin-Aggressive Antero-Posterior ROP-Mr U Mahmood.</li> </ul>	<p>Noted</p> <p>Noted, IFR has been sent off</p> <p>Noted</p>	<p>No further Action</p> <p>No Further Action</p> <p>No Further Action</p>			<p>12/16</p> <p>12/16</p> <p>12/16</p>
2016.12.12	<b>Committee Dates for 2017</b>	2 <sup>nd</sup> Thursday of each month. Dates have been circulated to all members.		No Further Action			12/16
2016.12.13	<b>Issues To Escalate To Operational Quality Committee</b>	None Noted		No Further Action			12/16
2016.12.14	<b>Any Other Business</b>	POB briefed the committee regarding the recent Pfizer patent case for Lyrica brand of pregabalin. The court had not upheld Pfizer's patent claim for only Lyrica use in neuropathic pain.	E mail to be sent to Department	POB to do	POB	01/17	

		<p>From Jan 17 HEY will be switching to generic for this indication, including patients that are admitted on Lyrica.</p> <p>POB had correspondence from Dr Dhadda, Consultant Clinical Oncologist, regarding patients receiving bisphosphonates as supportive therapy. To be discussed with commissioners at MMIG, as to how commissioned and supplied locally, e.g. IV in hospital and oral via the GP.</p>	<p>To be further discussed at MMIG.</p> <p>To be further discussed at MMIG</p>	<p>SG to agenda for MMIG</p> <p>SG to agenda for MMIG</p>	<p>SG</p> <p>SG</p>	<p>01/17</p> <p>01/17</p>	
2016.12.15	<b>Date and Time of Next Meeting</b>	<p><b>Date</b> - Thursday 12<sup>th</sup> January <b>Time</b> - 8.15am – 9.30am <b>Venue</b> - The Board Room, Alderson House, HRI</p>					